Original Research
Published on 09 Nov 2022
Designing a multi-epitope vaccine against coxsackievirus B based on immunoinformatics approaches
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.933594
- 3,635 views
Type at least 3 characters
2,517 articles
Articles
Original Research
Published on 08 Nov 2022
RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.974016
- 3,947 views
- 1 citation
Original Research
Published on 08 Nov 2022
Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.948335
- 3,740 views
- 1 citation
Brief Research Report
Published on 08 Nov 2022
A single birth dose of Hepatitis B vaccine induces polyfunctional CD4+ T helper cells
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1043375
- 1,818 views
Original Research
Published on 08 Nov 2022
Identification of potential candidate vaccines against Mycobacterium ulcerans based on the major facilitator superfamily transporter protein
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1023558
- 1,708 views
- 4 citations
Original Research
Published on 08 Nov 2022
Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1017590
- 1,950 views
- 3 citations
Original Research
Published on 07 Nov 2022
Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1030238
- 1,633 views
- 3 citations
Original Research
Published on 03 Nov 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1029269
- 5,983 views
- 11 citations
Original Research
Published on 02 Nov 2022
Immuno-informatics profiling of monkeypox virus cell surface binding protein for designing a next generation multi-valent peptide-based vaccine
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1035924
- 3,281 views
- 15 citations
Original Research
Published on 01 Nov 2022
The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational study
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1027924
- 1,562 views
- 3 citations
Original Research
Published on 31 Oct 2022
SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.960094
- 4,225 views
- 2 citations
Original Research
Published on 31 Oct 2022
Construction and protective efficacy of a novel Streptococcus pneumoniae fusion protein vaccine NanAT1-TufT1-PlyD4
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1043293
- 2,227 views
Original Research
Published on 31 Oct 2022
Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1033804
- 1,513 views
- 5 citations
Original Research
Published on 31 Oct 2022
An ambient-temperature stable nanoparticle-based vaccine for nasal application that confers long-lasting immunogenicity to carried antigens
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1057499
- 1,235 views
- 1 citation
Original Research
Published on 31 Oct 2022
Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1021396
- 3,342 views
- 10 citations
Original Research
Published on 28 Oct 2022
The magnitude of the germinal center B cell and T follicular helper cell response predicts long-lasting antibody titers to plague vaccination
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1017385
- 1,921 views
- 2 citations